Applying selective biophysical techniques in assessing the comparability of protein therapeutics - Case studies

American Pharmaceutical Review

Volumn 9, Issue 4, 2006, Pages 34-43

  Jiang, Yijia ^a   Narhi, Linda Owers ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; FLUORESCENCE ANALYSIS; INFRARED SPECTROSCOPY; MOLECULAR INTERACTION; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; REVIEW; SCREENING TEST; THERMOSTABILITY; ULTRACENTRIFUGATION;

EID: 55749108733     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. FDA guidance concerning demonstration of comparability of human biological products, including therapeutic biotechnologyderived products, CBER and CDER, April, 1996.
2. Chirino A.J. and Mire-Sluis A., Characterizing biological products and assessing comparability following manufacturing changes, Nature Biotechnology, 22 (11), 1383-1391, 2004.
3. Chi E. Y., Krishnan S., Randolph T. W. and Carpenter J. F., Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation, Pharmaceutical research, 20 (9), 1325-1336, 2003.
4. Sanyal G., Marquis-Omer D., Middaugh C. R., Biophysical characterization and formulation of TP40: A chimeric protein that requires a pH-dependent conformational change for its biological activity, Formulation, characterization and stability of protein drugs, Plenum Press, 365-392, 1996.
5. Carpenter, J F. Prestrelski, S J. Dong, A., Application of infrared spectroscopy to development of stable lyophilized protein formulations, European Journal of Pharmaceutics & Biopharmaceutics, 45(3): 231-8, 1998.
6. Volkin D.B., Burke C. J., Marfia K., Oswald C. B., Wolanski B., and Middaugh C.R., Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine, Journal of pharmaceutical sciences, 86 (6), 666-673, 1997.
7. Brorson K. and Phillips J., Defining your product profile and maintaining control over it, Part 4. Productrelated impurities: tackling aggregates, Bioprocess technical, 50-54, 2005 (6).
8. Li T. Yamane H. Arakawa T. Narhi LO. Philo J. Effect of the intermolecular disulfide bond on the conformation and stability of glial cell line-derived neurotrophic factor., Protein Engineering, 15(1): 59- 64, 2002.